Company profile
BIONTECH SE
NASDAQ:BNTXBiotechnology: Biological Products (No Diagnostic Substances)
Drug pipeline (7)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| COMIRNATY | approved | — | 0 | — |
| TRASTUZUMAB PAMIRTECAN | phase3 | — | 1 | active |
| AUTOGENE CEVUMERAN | phase2 | — | 1 | active |
| BNT-152 MRNA | phase1 | — | 1 | no active trials |
| BNT-153 MRNA | phase1 | — | 1 | no active trials |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (83)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05988203 | phase1_2 | completed | 2023-09-21 | 2025-08-25 | BioNTech SE | A Clinical Study Investigating the Safety and Immune Responses After Immunization With Investigational Monkeypox Vaccines |
| NCT06940804 | phase2 | withdrawn | 2025-07-01 | 2042-06-01 | BioNTech SE | A Clinical Study Investigating the Therapeutic Effects and Safety of an Investigational Cell Therapy Given With and Without an Additional Investigational Product in Males With Testicular Cancer or a Form of Cancer That Developed From Sperm |
| NCT06340568 | phase3 | recruiting | 2025-06-10 | 2028-03-01 | BioNTech SE | A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer |
| NCT04625205 | phase1 | terminated | 2020-12-01 | 2025-03-26 | BioNTech US Inc. | A Clinical Study of the Safety and Activity of the Investigational Cell Therapy NEO-PTC-01 in Patients With Advanced Melanoma |
| NCT04503278 | phase1 | active_not_recruiting | 2020-09-16 | 2028-08-01 | BioNTech Cell & Gene Therapies GmbH | A Clinical Study of the Safety and Effectiveness of an Investigational Cell Therapy Given With and Without an Investigational RNA-based Vaccine in Patients With Organ Tumors |
FDA applications (1)
| Application | Approved | Type | Applicant | Products | ||||
|---|---|---|---|---|---|---|---|---|
| BLA 125742 | 2021-08-23 | BLA | BIONTECH MANUFACTURING GMBH | |||||
Loading… | ||||||||